REG - Oxford Biomedica PLC - Result of AGM <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

15/07/2015 16:33

RNS Number : 5117M
Oxford Biomedica PLC
07 May 2015
Oxford BioMedica Annual General Meeting
London, UK - 7 May 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.
In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:
 Resolution 14: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and
 Resolution 15: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice. 
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolutions passed at the 2015 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
The results of the proxy voting in advance of the meeting are shown below. On the Record Date (5 May 2015) there were 2,568,040,015 1p ordinary shares in issue, each carrying one vote per share.
Resolution
Votes
For
Votes at
Chairman's
Discretion
Votes at
other proxy
Discretion
Votes
Against
Votes
Withheld
Total
votes cast
Result








Ordinary resolutions













1
1,569,855,529
997,910
3,429,924
44,395
37,743
1,574,365,501
Passed








2
1,568,499,344
1,124,976
3,429,924
1,144,667
166,590
1,574,365,501
Passed








3
1,559,509,773
1,151,115
3,429,924
2,231,914
8,042,775
1,574,365,501
Passed
4
 1,565,366,633
998,823
3,429,924
4,512,371
45,191
1,574,352,942
Passed








5
1,565,363,916
998,823
3,429,924
4,513,033
47,246
1,574,352,942
Passed








6
1,565,365,962
998,823
3,429,924
4,503,033
55,200
1,574,352,942
Passed








7
1,565,355,486
996,203
3,429,924
4,512,371
58,958
1,574,352,942
Passed








8
1,569,730,217
1,000,773
3,429,924
116,408
88,179
1,574,365,501
Passed








9
1,559,704,929
1,052,832
3,429,924
2,148,027
8,029,789
1,574,365,501
Passed








10
1,561,084,685
1,108,626
3,429,924
846,210
7,896,056
1,574,365,501
Passed








11
1,561,001,842
1,068,751
3,429,924
966,478
7,898,506
1,574,365,501
Passed








12
 1,569,491,544
1,060,845
3,429,924
190,709
192,479
1,574,365,501
Passed








13
1,569,481,603
1,057,412
3,429,924
249,740
146,822
1,574,365,501
Passed








Special resolutions













14
1,568,482,462
1,155,736
3,429,924
1,090,080
207,299
1,574,365,501
Passed








15
1,566,284,325
1,208,555
3,429,924
3,313,737
128,960
1,574,365,501
Passed








The following resolution was taken on a poll called by the Chairman of the Company at the meeting:
 Resolution 15: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.
The results of the votes cast were as follows:
Votes For
Votes Against
Votes Withheld
Total Votes Cast
Result
1,583,347,994
6,562,802
7,731,340
1,589,910,796
Passed
The number of votes validly cast in relation to Resolution 15 was 1,589,910,796, which constitutes 61.91% of the issued share capital of the Company.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk .

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGSSUFFWFISEII